-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Stenoparib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stenoparib in Solid Tumor Drug Details: Stenoparib (E-7449) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Solid Tumor Drug Details: Dovitinib lactate (TKI258,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Metastatic Ovarian Cancer Drug Details: Dovitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Stenoparib in Lung Cancer Drug Details: Stenoparib (E-7449) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Stenoparib in Triple-Negative Breast Cancer (TNBC) Drug Details: Stenoparib (E-7449) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Stenoparib in Pancreatic Cancer Drug Details: Stenoparib (E-7449) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Stenoparib in Mantle Cell Lymphoma Drug Details: Stenoparib (E-7449) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Ovarian Cancer
Stenoparib (E-7449) is under development for the treatment of solid tumors, ovarian cancer, metastatic breast cancer, pediatric cancers such as solid tumors, neuroblastoma, sarcomas and CNS tumors. It is also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route as a capsule. It acts by targeting PARP 1 and 2 and tankyrase 1 and 2. It was also under development for endometrial...